Literature DB >> 18252231

Sequence alterations within CYP7B1 implicate defective cholesterol homeostasis in motor-neuron degeneration.

Maria K Tsaousidou1, Karim Ouahchi, Tom T Warner, Yi Yang, Michael A Simpson, Nigel G Laing, Philip A Wilkinson, Ricardo E Madrid, Heema Patel, Faycal Hentati, Michael A Patton, Afif Hentati, Philippa J Lamont, Teepu Siddique, Andrew H Crosby.   

Abstract

The hereditary spastic paraplegias (HSPs) are a genetically and clinically heterogeneous group of upper-motor-neuron degenerative diseases characterized by selective axonal loss in the corticospinal tracts and dorsal columns. Although numerous mechanisms involving defective subcellular transportation, mitochondrial malfunction, and increased oxidative stress have been proposed, the pathogenic basis underlying the neuronal loss is unknown. We have performed linkage analysis to refine the extent of the SPG5 disease locus and conducted sequence analysis of the genes located within this region. This identified sequence alterations in the cytochrome P450-7B1 (CYP7B1) associated with this pure form of HSP. In the liver, CYP7B1 offers an alternative pathway for cholesterol degradation and also provides the primary metabolic route for the modification of dehydroepiandrosterone neurosteroids in the brain. These findings provide the first direct evidence of a pivotal role of altered cholesterol metabolism in the pathogenesis of motor-neuron degenerative disease and identify a potential for therapeutic intervention in this form of HSP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18252231      PMCID: PMC2426914          DOI: 10.1016/j.ajhg.2007.10.001

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  33 in total

Review 1.  Cytochrome-P450 phosphorylation as a functional switch.

Authors:  Barbara Oesch-Bartlomowicz; Franz Oesch
Journal:  Arch Biochem Biophys       Date:  2003-01-01       Impact factor: 4.013

Review 2.  Is the transportation highway the right road for hereditary spastic paraplegia?

Authors:  Andrew H Crosby; Christos Proukakis
Journal:  Am J Hum Genet       Date:  2002-09-24       Impact factor: 11.025

3.  Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis.

Authors:  P T Clayton; A Verrips; E Sistermans; A Mann; G Mieli-Vergani; R Wevers
Journal:  J Inherit Metab Dis       Date:  2002-10       Impact factor: 4.982

4.  A clinical and genetic study of SPG5A linked autosomal recessive hereditary spastic paraplegia.

Authors:  P A Wilkinson; A H Crosby; C Turner; H Patel; N W Wood; A H Schapira; T T Warner
Journal:  Neurology       Date:  2003-07-22       Impact factor: 9.910

5.  Disruption of the oxysterol 7alpha-hydroxylase gene in mice.

Authors:  J Li-Hawkins; E G Lund; S D Turley; D W Russell
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

6.  Frontal lobe dementia with abnormal cholesterol metabolism and heterozygous mutation in sterol 27-hydroxylase gene (CYP27).

Authors:  S Sugama; A Kimura; W Chen; S Kubota; Y Seyama; N Taira; Y Eto
Journal:  J Inherit Metab Dis       Date:  2001-06       Impact factor: 4.982

7.  Hypercholesterolemia and changes in lipid and bile acid metabolism in male and female cyp7A1-deficient mice.

Authors:  Sandra K Erickson; Steven R Lear; Sean Deane; Sandrine Dubrac; Sandra L Huling; Lien Nguyen; Jaya S Bollineni; Sarah Shefer; Hideyuki Hyogo; David E Cohen; Benjamin Shneider; Ephraim Sehayek; Meena Ananthanarayanan; Natarajan Balasubramaniyan; Fredrick J Suchy; Ashok K Batta; Gerald Salen
Journal:  J Lipid Res       Date:  2003-02-16       Impact factor: 5.922

8.  7-Hydroxylated epiandrosterone (7-OH-EPIA) reduces ischaemia-induced neuronal damage both in vivo and in vitro.

Authors:  Ashley K Pringle; Werner Schmidt; Jackie K Deans; Ernst Wulfert; Klaus G Reymann; Lars E Sundstrom
Journal:  Eur J Neurosci       Date:  2003-07       Impact factor: 3.386

9.  Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype.

Authors:  Clive R Pullinger; Celeste Eng; Gerald Salen; Sarah Shefer; Ashok K Batta; Sandra K Erickson; Andrea Verhagen; Christopher R Rivera; Sean J Mulvihill; Mary J Malloy; John P Kane
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

10.  Spastic paraplegia 5: Locus refinement, candidate gene analysis and clinical description.

Authors:  Stephan Klebe; Alexandra Durr; Naima Bouslam; Djamel Grid; Caroline Paternotte; Christel Depienne; Sylvain Hanein; Ahmed Bouhouche; Nizar Elleuch; Hamid Azzedine; Sandrine Poea-Guyon; Sylvie Forlani; Elodie Denis; Céline Charon; Jamile Hazan; Alexis Brice; Giovanni Stevanin
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2007-10-05       Impact factor: 3.568

View more
  69 in total

1.  Treatment of SPG5 with cholesterol-lowering drugs.

Authors:  Andrea Mignarri; Alessandro Malandrini; Marina Del Puppo; Alessandro Magni; Lucia Monti; Federica Ginanneschi; Alessandra Tessa; Filippo Maria Santorelli; Antonio Federico; Maria Teresa Dotti
Journal:  J Neurol       Date:  2015-11-14       Impact factor: 4.849

2.  An analysis of exome sequencing for diagnostic testing of the genes associated with muscle disease and spastic paraplegia.

Authors:  Cristina Dias; Murat Sincan; Praveen F Cherukuri; Rosemarie Rupps; Yan Huang; Hannah Briemberg; Kathryn Selby; James C Mullikin; Thomas C Markello; David R Adams; William A Gahl; Cornelius F Boerkoel
Journal:  Hum Mutat       Date:  2012-02-28       Impact factor: 4.878

Review 3.  Recent advances in the genetics of spastic paraplegias.

Authors:  Giovanni Stevanin; Merle Ruberg; Alexis Brice
Journal:  Curr Neurol Neurosci Rep       Date:  2008-05       Impact factor: 5.081

4.  Liver disease in infancy caused by oxysterol 7 α-hydroxylase deficiency: successful treatment with chenodeoxycholic acid.

Authors:  Dongling Dai; Philippa B Mills; Emma Footitt; Paul Gissen; Patricia McClean; Jens Stahlschmidt; Isabelle Coupry; Julie Lavie; Fanny Mochel; Cyril Goizet; Tatsuki Mizuochi; Akihiko Kimura; Hiroshi Nittono; Karin Schwarz; Peter J Crick; Yuqin Wang; William J Griffiths; Peter T Clayton
Journal:  J Inherit Metab Dis       Date:  2014-09       Impact factor: 4.982

Review 5.  Overcoming the divide between ataxias and spastic paraplegias: Shared phenotypes, genes, and pathways.

Authors:  Matthis Synofzik; Rebecca Schüle
Journal:  Mov Disord       Date:  2017-02-14       Impact factor: 10.338

6.  Is the gene-environment interaction paradigm relevant to genome-wide studies? The case of education and body mass index.

Authors:  Jason D Boardman; Benjamin W Domingue; Casey L Blalock; Brett C Haberstick; Kathleen Mullan Harris; Matthew B McQueen
Journal:  Demography       Date:  2014-02

7.  Analysis of CYP7B1 in non-consanguineous cases of hereditary spastic paraplegia.

Authors:  Rebecca Schüle; Elisabeth Brandt; Kathrin N Karle; Maria Tsaousidou; Stephan Klebe; Sven Klimpe; Michaela Auer-Grumbach; Andrew H Crosby; Christian A Hübner; Ludger Schöls; Thomas Deufel; Christian Beetz
Journal:  Neurogenetics       Date:  2008-10-15       Impact factor: 2.660

8.  Interaction of the SPG21 protein ACP33/maspardin with the aldehyde dehydrogenase ALDH16A1.

Authors:  Michael C Hanna; Craig Blackstone
Journal:  Neurogenetics       Date:  2009-01-31       Impact factor: 2.660

9.  Novel SPG11 mutations in Asian kindreds and disruption of spatacsin function in the zebrafish.

Authors:  Laura Southgate; Dimitra Dafou; Jacqueline Hoyle; Nan Li; Esther Kinning; Peter Critchley; Andrea H Németh; Kevin Talbot; Parayil S Bindu; Sanjib Sinha; Arun B Taly; Seetharam Raghavendra; Ferenc Müller; Eamonn R Maher; Richard C Trembath
Journal:  Neurogenetics       Date:  2010-10       Impact factor: 2.660

10.  Mutations in phospholipase DDHD2 cause autosomal recessive hereditary spastic paraplegia (SPG54).

Authors:  Michael Gonzalez; Sheela Nampoothiri; Cornelia Kornblum; Andrés Caballero Oteyza; Jochen Walter; Ioanna Konidari; William Hulme; Fiorella Speziani; Ludger Schöls; Stephan Züchner; Rebecca Schüle
Journal:  Eur J Hum Genet       Date:  2013-03-13       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.